Charles P. Theuer | President and CEO |
Scott B. Brown | Chief Financial Officer |
Joel Beatty | Robert W. Baird |
Edward White | H.C. Wainwright |
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals’ Second Quarter 2023 Earnings Conference Call. At this time, all callers are in a listen-only mode. After the speakers’ prepared remarks, we'll conduct a question-and-answer session and instructions will be given at that time.
During today's call, we will be making certain forward-looking statements including statements regarding expected timing of clinical trials and results of regulatory activities, financing opportunities, future expenses, and cash runway, our development plan and strategy and with the recovery of the award from our arbitration with I-Mab. These statements are subject to various risks that are described in our filings made with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2022, and subsequent quarterly reports on Form 10-Q.